

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-93. (Cancelled).

94. (Currently Amended) A method for treating a mammal suffering from or susceptible to ~~diseases causing apoptosis or apoptosis-like death of cells, except for treatment of immune deficiency, which a brain infarction~~ comprising administering to the brain cells of the mammal a composition comprising ~~ginseng extracts, or ginseng components~~ ginsenoside Rb₁, its metabolites or salts thereof, wherein doses or dosages of ~~ginseng extracts~~ ginsenoside Rb₁ are adjusted to ~~between 145 pg/kg/day and 1450 µg/kg/day, and those of ginseng components are~~ adjusted to be between 1.67 pg/kg/day and 1.67 mg/kg/day.

95-107. (Cancelled).

108. (Currently Amended) The method according to claim 94, wherein the brain cells are nerve cells or neurons.

109. (Currently Amended) The method according to claim 108, wherein the diseases causing ~~apoptosis or apoptosis-like~~ death of nerve cells or neurons is cerebral infarction or cerebral apoplexy.

110-118. (Canceled)

119. (Previously Presented) The method according to any one of claims 94, 108 and 109, wherein the composition comprises ginsenoside Rb₁ and it is administered intravenously in a dose range of 0.167 µg/kg/day to 1.67 mg/kg/day.

120. (Previously Presented) The method according to any one of claims 94, 108 and 109, wherein the composition comprises ginsenoside Rb₁ and it is administered intravenously in a dose range of 1.67pg/kg/day to 1.67mg/kg/day.